CN1565446A - 注射用氟康唑冻干制剂及制备方法 - Google Patents
注射用氟康唑冻干制剂及制备方法 Download PDFInfo
- Publication number
- CN1565446A CN1565446A CNA031431550A CN03143155A CN1565446A CN 1565446 A CN1565446 A CN 1565446A CN A031431550 A CNA031431550 A CN A031431550A CN 03143155 A CN03143155 A CN 03143155A CN 1565446 A CN1565446 A CN 1565446A
- Authority
- CN
- China
- Prior art keywords
- injection
- bottle
- acid
- fluconazole
- lyophilized formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000004108 freeze drying Methods 0.000 title claims abstract description 7
- 229940091713 fluconazole injection Drugs 0.000 title abstract 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000243 solution Substances 0.000 claims abstract description 25
- 229960004884 fluconazole Drugs 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 30
- 238000009472 formulation Methods 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229920005549 butyl rubber Polymers 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000000413 hydrolysate Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 235000010338 boric acid Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims description 2
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000013505 freshwater Substances 0.000 claims 3
- 238000009835 boiling Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 229940119744 dextran 40 Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- -1 ll Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种注射用氟康唑冻干制剂及制备方法。本发明所述冻干制剂是将活性药物氟康唑(50-200mg/每瓶)加入一定量的支架剂,pH值调节剂,增溶剂配成一定浓度的溶液后,灌装于管制抗生素西林瓶内进行冷冻干燥40-48小时,即可制成质地疏松,极溶于水的块状冻干制剂。本发明的注射用氟康唑冻干制剂具有良好的药物稳定性,使用有效期限长,临床使用和携带、运输都很方便,为氟康唑在临床使用上提供了又一新的制剂,该制剂供临床静脉滴注给药,可广泛应用于各种真菌感染患者以及预防真菌感染。
Description
技术领域
本发明涉及的是医药领域中的药物制剂,尤其是涉及一种具有广谱抗真菌作用的注射用氟康唑冻干制剂及制备方法。
背景技术
氟康唑(C13H12F2N6O,分子量:306.28)为一种白色结晶性粉末,在甲醇中易溶,在乙醇中溶解,在水中微溶,它是新型三唑类抗真菌药物,有广谱抗真菌作用,能选择性地抑制真菌的甾醇合成,对真菌细胞色素P-450依赖酶的抑制作用具有高度选择性。它在体内外对隐球菌属、念球菌属、黄曲菌、烟曲菌、皮炎芽生菌、粗球孢子菌、荚膜组织胞浆菌均显示有良好的抗菌作用。它与蛋白结合率较低,且生物利用度高,并具有穿透中枢的特点,是临床抗真菌感染的首选药物,还可以用于治疗或预防滥用抗生素造成菌群失调后的真菌感染患者。由于艾滋病患者免疫低陷,粘膜特别容易感染真菌,所以该药还可用于艾滋病患者防真菌感染的治疗。
静脉滴注给药起效快,临床上往往对一些重症患者或口服有困难的患者实施静脉滴注给药。临床上供静脉滴注的氟康唑制剂有:用氯化钠或葡萄糖调节等渗的100ml中含200mg氟康唑的大容量注射液(大输液)以及10ml中含100mg氟康唑和5ml中含200mg氟康唑的小容量注射液(小针剂)。因为氟康唑的水溶性差,制备小容量注射液时常常采用加入有机溶剂的方法,增加氟康唑在溶液中的溶解度,一般加入丙二醇溶剂,而该溶剂的粘度大,配制的注射液很稠,在使用时容易造成稀释剂量不准确,也会给患者带来一定的不良反应。再就是活性药物氟康唑长时间的处于溶液状态,易受自然因素的影响而发生氧化、水解等变化,不利于药物的稳定。溶液型的注射剂在运输上也容易造成破损,不利于药物的携带和运输。为克服上述各种不利因素,我们研制开发注射用氟康唑冻干制剂,采用管制抗生素西林瓶包装,丁基胶塞及铝盖封口,它能有效的克服溶液型注射剂存在的不足。该冻干制剂为白色块状物,质地疏松,加少量水(3-10ml)可迅速溶解,再将溶解后的溶液加入氯化钠或葡萄糖的等渗注射液中用于临床。该冻干制剂药物稳定性良好,使用有效期限长,临床使用和携带、运输都很方便。为氟康唑在临床使用上提供了又一新的制剂。
发明内容
本发明的目的在于提供一种有利于药物的稳定,易于携带和运输,临床使用方便的注射用氟康唑冻干制剂及制备方法。
本发明所述注射用氟康唑冻干制剂优点是:避免活性药物因加热或长时间处于溶液状态而分解变质,增加了药物的稳定性,冻干制剂质地疏松,加少量水即可溶解,可延长药物的贮存期,临床使用方便,无制剂剂型引起的不良反应。
本发明所述的注射用氟康唑冻干剂制是这样实现的:本发明的配方由以下成份组成(每瓶含量):
氟康唑 50-200mg
支架剂(填充剂) 2-200mg
PH值调节剂 0.1-100mg
增溶剂 0.1-50mg
注射用水 加至 2-10ml
本发明所述冻干制剂的配方中活性药物氟康唑含量为:每瓶为50mg或100mg或200mg。
本发明所述冻干制剂中支架剂(填充剂)为:乳糖、甘露醇、右旋糖酐、葡萄糖、水解明胶、山梨醇、氨基酸、氯化钠、氯化钙、蔗糖、聚维酮、枸椽钠、磷酸钠盐等中的一种或两种以上的混合物,优选:乳糖、甘露醇、右旋糖酐、水解明胶。
本发明所述冻干制剂中PH值调节剂为:盐酸、醋酸、乳酸、甲磺酸、磷酸、枸椽酸、硼酸、酒石酸、苹果酸、氨基酸、碳酸钠、碳酸氢钠、氢氧化钠等中一种或两种以上的混合和的,优选乳酸、甲磺酸、醋酸、枸椽酸、碳酸氢钠、氢氧化钠。
本发明所述冻干制剂中增溶剂为:吐温-80、泊洛沙姆、聚乙二醇、聚维酮等中的一种。
本发明制备方法为:
1.将处方量的氟康唑、支架剂、增溶剂混合,加入一定量注射用水,再用PH值调节剂配成一定浓度的溶液或按处方量直接加入后,搅拌使全部溶解(可加热至60-80C或煮沸),调节PH值为3-6,再用注射用水加至处方规定的配制量。
2.将配制好的溶液加入每瓶3-10mg的活性炭煮沸后,搅拌吸附15分钟,用砂芯滤棒或3号垂熔漏斗过滤除去活性炭,滤液再经Φ0.22um微孔滤膜精滤,经中间体检测合格后即可按处方量分装于15ml管制抗生素西林瓶内,每瓶内分装溶液2-10ml。
3.将分装好溶液的管制抗生素西林瓶置真空冷冻干燥箱内,按冷冻干燥的操作程序进行真空冷冻干燥,冷冻干燥时间40-48小时后,开启干燥箱,瓶口加丁基胶塞盖,并轧封铝盖,即得成品。
具体实施方式
下面结合实施例对本发明作进一步详细说明,但应理解本明的范围非仅限于这些实施例的范围。
实施例1
配方1:每瓶冻干制剂含氟康唑50mg
氟康唑 500mg
甘露醇 500mg
右旋糖酐40 100mg
1mol/L HCl溶液 5ml
1mol/L NaOH溶液 适量调PH
吐温-80 25mg
注射用水 加至 30ml
分装10瓶,每瓶3ml
制备方法:取处方中氟康唑加入吐温-80、1mol/L HCl溶液,在60-80℃水浴中加热,搅拌使氟康唑全部溶解,加入约总量80%的注射用水,用1mol/L NaOH溶液调PH值至3-5,加入处方量的甘露醇、右旋糖酐40、搅拌使全部溶解,加入30mg的活性炭,并加注射用水至处方全量,煮沸后搅拌15分钟。用3号垂熔漏斗过滤除去活性炭,滤液再用5号垂熔漏斗精滤。经检测,滤液符合规定后分装于管制抗生素西林瓶内,敞口放置真空冷冻干燥箱内进行冷冻干燥48小时,用丁基胶塞盖紧瓶口,并轧封铝盖即得成品。
实施例2
配方2:每瓶冻干制剂含氟康唑100mg
氟康唑 1000mg
乳糖 1000mg
50%乳酸 7ml
0.2mol/L磷酸二氢钠 10ml
1mol/L NaOH溶液 适量调PH
吐温-80 40mg
注射用水 加至 40ml
分装10瓶,每瓶4ml
制备方法:取处方中氟康唑加入吐温-80、50%乳酸、0.2mol/L磷酸二氢钠溶液加热搅拌,使氟康唑全部溶解,用1mol/L NaOH调溶液PH2-5,加入处方量的乳糖,搅拌使全部溶解,加入40mg的活性炭,并加注射用水至处方全量,煮沸后搅拌15分钟。其它方法同实施例1。
实施例3
配方3:每瓶冻干制剂含氟康唑150mg
配方1:每瓶冻干制剂含氟康唑50mg
氟康唑 500mg
右旋糖酐40 750mg
枸椽酸(无水) 75mg
0.2mol/L磷酸二氢钠 10ml
1mol/L NaOH溶液 适量调PH
吐温-80 40mg
注射用水 加至 50ml
分装10瓶,每瓶5ml
制备方法:取处方中氟康唑、右旋糖酐40、枸椽酸、0.2mol/L磷酸二氢钠、吐温-80加入注射用水约40ml,在80℃水浴中加热并搅拌使全部溶解,用0.5mol/L NaOH调溶液PH2-4,加入40mg的活性炭,并加注射用水至处方全量,煮沸后搅拌15分钟。其它方法同实施例1。
实施例4
配方4:每瓶冻干制剂含氟康唑200mg
氟康唑 2000mg
甘露醇 400mg
水解明胶 400mg
甲磺酸 2g
0.5mol/L NaOH溶液 适量调PH
吐温-80 50mg
注射用水 加至 50ml
分装10瓶,每瓶5ml
制备方法:取处方中氟康唑、甘露醇、水解明胶、甲磺酸、吐温-80加入注射用水约40ml,在80℃水浴中加热并搅拌使全部溶解,用0.5mol/LNaOH调溶液PH 2-5,加入50mg的活性炭,并加注射用水至处方全量,煮沸后搅拌15分钟。其它方法同实施例1。
Claims (7)
1.一种注射用氟康唑冻干制剂,其特征在于:每瓶含氟康唑50-200mg以及其它成份组成:
氟康唑 50-200mg
支架剂(填充剂) 2-200mg
PH值调节剂 0.1-100mg
增溶剂 0.1-50mg
新鲜注射用水 加至 2-10ml
2.制备如权利要求1所述的注射用氟康唑冻干制剂的制备方法,其特征在于:
(1)将处方量的氟康唑、支架剂、增溶剂混合,加入一定量新鲜注射用水,再用PH值调节剂配成一定浓度的溶液或按处方量加入后,搅拌使全部溶解(可加热至60-80℃或煮沸),调节PH值为2-5,再用新鲜注射用水加至处方规定的配制量。
(2)将配制好的溶液加入每瓶3-10mg的活性炭,煮沸后,搅拌吸附15分钟,用砂芯滤棒或3号垂熔漏斗过滤除去活性炭,滤液再经Φ0.22um微孔滤膜精滤,滤液经中间体检测合格后,即可按处方量分装于10-15ml管制抗生素西林瓶内,每瓶分装溶液2-10ml。
(3)将分装好溶液的西林瓶置真空冷冻干燥箱内,按冷冻干燥的操作程序进行真空冷冻干燥,冷冻干燥时间40-48小时后,开启干燥箱,加丁基胶塞盖,轧封铝盖,即得成品。
3.权利要求1所述的注射用氟康唑冻干制剂,其配方中的活性药物氟康唑含量为:每瓶50mg或每瓶100mg或每瓶150mg或每瓶200mg。
4.权利要求1所述的注射用氟康唑冻干制剂,其配方中的支架为:乳糖、甘露醇、右旋糖酐、葡萄糖、水解明胶、山梨醇、氨基酸、氯化钠、氯化钙、蔗糖、聚维酮、枸椽酸钠、磷酸钠盐等中的一种或两种以上的混合物,优选:乳糖、甘露醇、右旋糖酐、水解明胶。
5.权利要求1所述的注射用氟康唑冻干制剂,其配方中的PH值调节剂:盐酸、醋酸、乳酸、甲磺酸、磷酸、枸椽酸、硼酸、酒石酸、苹果酸、氨基酸、碳酸钠、碳酸氢钠、氢氧化钠等中的一种或两种以上的混合物。优选:乳酸、甲磺酸、醋酸、枸椽酸、碳酸氢钠、氢氧化钠。
6.权利要求1所述的注射用氟康唑冻干制剂,其配方中的增溶剂为:吐温-80、泊洛沙姆、聚乙二醇、聚维酮等中的一种,最为合适的增溶剂为吐温-80。
7.权利要求1所述的注射用氟康唑冻干制剂,其加入注射用水配成一定浓度溶液的最佳体积为:每瓶为3ml或5ml,灌装于10ml或15ml管制抗生素西林瓶内进行冷冻干燥。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031431550A CN1565446A (zh) | 2003-06-17 | 2003-06-17 | 注射用氟康唑冻干制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031431550A CN1565446A (zh) | 2003-06-17 | 2003-06-17 | 注射用氟康唑冻干制剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1565446A true CN1565446A (zh) | 2005-01-19 |
Family
ID=34471278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA031431550A Pending CN1565446A (zh) | 2003-06-17 | 2003-06-17 | 注射用氟康唑冻干制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1565446A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103877031A (zh) * | 2014-02-21 | 2014-06-25 | 安徽省先锋制药有限公司 | 一种常温稳定的福司氟康唑冻干制剂组合物及其制备方法 |
CN104873468A (zh) * | 2014-02-27 | 2015-09-02 | 陕西合成药业股份有限公司 | 一种注射用福司氟康唑及其制备方法和用途 |
CN104940133A (zh) * | 2015-06-11 | 2015-09-30 | 山东新时代药业有限公司 | 氟康唑注射液及其制备方法 |
CN104940135A (zh) * | 2015-07-11 | 2015-09-30 | 鲁南贝特制药有限公司 | 一种氟康唑注射液及其制备方法 |
CN106265540A (zh) * | 2016-08-31 | 2017-01-04 | 安徽省润生医药股份有限公司 | 一种福司氟康唑冻干制剂组合物及其制备方法 |
-
2003
- 2003-06-17 CN CNA031431550A patent/CN1565446A/zh active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103877031A (zh) * | 2014-02-21 | 2014-06-25 | 安徽省先锋制药有限公司 | 一种常温稳定的福司氟康唑冻干制剂组合物及其制备方法 |
CN104873468A (zh) * | 2014-02-27 | 2015-09-02 | 陕西合成药业股份有限公司 | 一种注射用福司氟康唑及其制备方法和用途 |
CN104940133A (zh) * | 2015-06-11 | 2015-09-30 | 山东新时代药业有限公司 | 氟康唑注射液及其制备方法 |
CN104940135A (zh) * | 2015-07-11 | 2015-09-30 | 鲁南贝特制药有限公司 | 一种氟康唑注射液及其制备方法 |
CN106265540A (zh) * | 2016-08-31 | 2017-01-04 | 安徽省润生医药股份有限公司 | 一种福司氟康唑冻干制剂组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1138541C (zh) | 一种药学上稳定的奥沙利铂制剂 | |
KR101113084B1 (ko) | 파론노세트론의 액체 약제학적 제제 | |
US20110178470A1 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
CN1371366A (zh) | 具有组蛋白脱乙酰酶抑制剂活性的苯甲酰胺制剂 | |
CN1668332A (zh) | 包含苯酚的含高浓度人生长激素的液体制剂 | |
WO2016098009A1 (en) | Lyophilized injectable compositions of daptomycin | |
CN101584668A (zh) | 盐酸苯达莫司汀冻干粉针剂 | |
CN1823768A (zh) | 西咪替丁冻干组合物 | |
CN1565446A (zh) | 注射用氟康唑冻干制剂及制备方法 | |
CN1245987C (zh) | 一种稳定性提高的灯盏花素注射剂及其制备方法 | |
CN112402371B (zh) | 一种瑞德西韦注射液及其制备方法 | |
EP2887953A2 (en) | Improved daptomycin injectable formulation | |
CN1897940A (zh) | 用于非经肠胃给药的长春氟宁医药组合物及其制备方法和用途 | |
CN1259041C (zh) | 注射用盐酸溴己新无菌冻干制剂及其制备方法 | |
WO2015025000A1 (en) | Pharmaceutical compositions comprising bortezomib | |
CN102657624B (zh) | 高光学纯度反式-右旋奥沙利铂冻干粉针剂及其制备方法 | |
CN101912361A (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
US11957758B2 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
CN111603439A (zh) | 一种长效依匹哌唑原位相变凝胶注射剂及其制备方法 | |
CN101125125A (zh) | 马来酸甲麦角新碱粉针剂及其制备方法 | |
CN1186094C (zh) | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 | |
CN1442138A (zh) | 氟康唑注射液及其制备方法 | |
CN102626411A (zh) | 丙泊酚与阿片类镇痛剂的药物组合物及其应用 | |
CN1839842A (zh) | 一种含左西孟旦或其药学上可以接受的盐作为活性成分的药物组合物 | |
CN1820748A (zh) | 一种左旋奥硝唑冻干粉针注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |